Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical observations with AN-1792 using TAPIR analyses.

Christoph Hock1, Roger M Nitsch

  • 1Division of Psychiatry Research, University of Zurich, Zurich, Switzerland. chock@bli.unizh.ch

Neuro-Degenerative Diseases
|August 16, 2006
PubMed
Summary

Antibodies targeting beta-amyloid plaques slowed Alzheimer's disease progression in humans. This proof-of-concept study shows potential for a cure by targeting specific A beta species.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.

Nature medicine·2026
Same author

Independent and interactive contributions of white matter hyperintensities and Alzheimer's disease imaging and plasma biomarkers to cognitive decline in older adults without dementia.

Alzheimer's research & therapy·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer's disease brain are associated with Aβ, tau pathologies and synaptic loss.

Alzheimer's research & therapy·2025
Same author

Predicting cognitive decline with amyloid-PET, plasma p-tau217, Aβ42/40, and p-tau217/Aβ42 in a community-based cohort - relevance for clinical trial enrollment.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer's disease: associations with Aβ, tau, synaptic proteins and APOE ε4.

Translational neurodegeneration·2025

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer's disease is characterized by the accumulation of beta-amyloid (A beta) plaques in the brain.
  • Current therapeutic strategies aim to clear or reduce A beta burden.
  • Developing effective treatments remains a significant challenge.

Purpose of the Study:

  • To present evidence that antibodies targeting beta-amyloid-related epitopes can slow Alzheimer's disease progression in humans.
  • To demonstrate the utility of tissue amyloid plaque immunoreactivity (TAPIR) analyses in identifying therapeutic targets.
  • To establish a proof-of-concept for a potential cure for Alzheimer's disease.

Main Methods:

  • Utilized AN-1792 clinical observations.
  • Employed tissue amyloid plaque immunoreactivity (TAPIR) assay selection.
  • Focused on antibodies targeting specific aggregated A beta species, including protofibrillar and oligomeric precursors.

Main Results:

  • Established the first human evidence that antibodies against beta-amyloid-related epitopes slow Alzheimer's disease progression.
  • Demonstrated that TAPIR-selected antibodies can specifically target pathologic neoepitopes on aggregated A beta species.
  • Confirmed the presence of these targeted epitopes in amyloid plaques and their precursors.

Conclusions:

  • Antibodies targeting specific beta-amyloid epitopes offer a promising therapeutic approach for Alzheimer's disease.
  • The TAPIR assay is a valuable tool for identifying and selecting effective antibodies.
  • This research provides a strong basis for the development of a potential cure for Alzheimer's disease.

Related Experiment Videos